Developer docs
API playgroundTry for free, no card

Search company profiles

Myovant Sciences

Full company profile

uuid00054wb

Namestring
Myovant Sciences
Legal namestring
Myovant Sciences Ltd.
Websiteurl
myovant.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Myovant Sciences is a specialty biopharmaceutical company developing and commercializing novel small-molecule therapies built on the relugolix platform. Its two marketed products are ORGOVYX (relugolix), indicated for advanced prostate cancer treatment, and MYFEMBREE (relugolix, estradiol, and norethindrone acetate), positioned across women's health indications including endometriosis and uterine fibroids. The company serves defined patient populations — men with advanced or castration-sensitive prostate cancer and women with endometriosis/uterine fibroids — through an enterprise specialty-pharma field-sales motion targeting healthcare providers and payers in the United States (North America accounts for 44.17% regional share of the 2025 endometriosis treatment market where Myovant competes).

Revenue is generated through branded pharmaceutical product sales of ORGOVYX and MYFEMBREE, with pricing negotiated with payers rather than publicly disclosed. The go-to-market relies on traditional specialty-pharma distribution channels reaching physicians and patients. Myovant is actively expanding its endometriosis clinical pipeline to include non-hormonal targeted therapies and long-term disease-management solutions, addressing a market projected to grow from USD 2.01 billion (2025) to USD 5.73–5.74 billion by 2034 at ~12.35–12.37% CAGR. ORGOVYX competes in a castration-sensitive prostate cancer market sized at USD 4.3 billion (2024) with 13.2% CAGR through 2034.

In March 2023, Myovant was acquired by Sumitovant Biopharma Ltd. for $1.7 billion, taking the company private and folding it into the Sumitomo Pharma America corporate ecosystem. Founded in 2016, headquartered in Brisbane, California, and operating with 501–1,000 employees, Myovant raised approximately $540 million across multiple private rounds (2017–2020) prior to acquisition, with Dainippon Sumitomo Pharma, Novaquest Capital Management, and Hercules Capital among its backers. As a wholly owned subsidiary, Myovant now leverages its parent's capital, R&D infrastructure, and commercial reach to accelerate pipeline development and franchise expansion.

Short descriptiontext

Myovant Sciences is a specialty biopharmaceutical company developing relugolix-based therapies — ORGOVYX for advanced prostate cancer and MYFEMBREE for women's health — serving prostate cancer patients and women with endometriosis and uterine fibroids as a Sumitovant Biopharma subsidiary.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersBrisbane, United States
HQ citystring
Brisbane
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
specialty biopharmaceuticals, prostate cancer therapy, women's health therapeutics, endometriosis treatment, novel drug development
Industry2 codes
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKAOAB
Urologic Oncology
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Myovant Sciences generates revenue from commercialization of its proprietary drug products ORGOVYX and MYFEMBREE. As a specialty biopharmaceutical company operating within Sumitovant Biopharma since the March 2023 acquisition, the revenue mix is anchored in product sales of approved therapies, with potential future revenue from expanded indications and pipeline products.

openpr.com
Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1ORGOVYX
Description

Novel therapy developed by Myovant Sciences, cited in connection with the Sumitovant acquisition.

openpr.com
+1 more record
Core offering1 text field

Myovant Sciences is a specialty biopharmaceutical company that develops and commercializes novel therapies for defined patient populations in prostate cancer and women's health. Its two lead products are ORGOVYX, an oral therapy for advanced prostate cancer, and MYFEMBREE, a therapy for women's health indications including endometriosis and uterine fibroids, supported by an actively expanding clinical pipeline for long-term endometriosis disease management.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Acquired by Sumitovant Biopharma for $1.7 billion in March 2023, signaling valuation of Myovant's portfolio of novel therapies.
+1 more record
Product overview1 text field

Myovant Sciences operates as a specialty biopharmaceutical company developing a focused portfolio of novel therapies rather than a platform-plus-modules software product. Its two named therapeutic products, ORGOVYX and MYFEMBREE, are the cornerstone offerings supported by an expanding clinical pipeline in women's health (endometriosis, uterine fibroids) and castration-sensitive prostate cancer. Following its March 2023 acquisition by Sumitovant Biopharma for $1.7 billion, Myovant's portfolio is positioned for accelerated development, and the company is cited as a key pharmaceutical player expanding clinical pipelines for long-term disease management in endometriosis and PCOS.

Product and service1 record
1ORGOVYX (relugolix)
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global pharmaceutical leader with a major women's health franchise (including Orilissa/Oriahnn for endometriosis) and oncology portfolio. Directly comparable as a key competitor cited in the endometriosis market alongside Myovant.

TypeBroad incumbent
Description

Diversified life sciences company with a significant women's health and oncology portfolio (e.g., Visanne for endometriosis). Named alongside Myovant as a key endometriosis market player.

TypeBroad incumbent
Description

Global pharmaceutical leader with established women's health and oncology franchises. Cited alongside Myovant as a key pharmaceutical company expanding endometriosis clinical pipelines.

TypeDirect peer
Description

Specialty biopharmaceutical company with deep urology and prostate cancer franchise (Xtandi). Directly comparable to Myovant's ORGOVYX positioning in advanced prostate cancer.

TypeDirect peer
Description

Women's health-focused specialty biopharmaceutical company spun out from Merck. Directly comparable to Myovant's MYFEMBREE franchise in endometriosis and uterine fibroids.

TypeDirect peer
Description

Specialty women's health biopharmaceutical company focused on hormone-related therapeutics, including uterine fibroid and menopause indications. Closely aligned with Myovant's MYFEMBREE women's health portfolio.

TypeBroad incumbent
Description

Global biopharmaceutical company with major oncology and women's health franchises. Comparable to Myovant as a broader incumbent with overlapping therapeutic areas.

TypeDirect peer
Description

Specialty biopharmaceutical company with established reproductive health and urology franchises. Directly comparable specialty peer to Myovant in women's health and prostate cancer therapeutics.

TypeBroad incumbent
Description

Diversified global pharmaceutical leader with significant oncology and women's health investments. Comparable broad-incumbent competitor operating in Myovant's therapeutic categories.

TypeDirect peer
Description

Specialty pharmaceutical company focused on urology and oncology, including prostate cancer treatments. Directly comparable specialty competitor to Myovant in the urologic oncology space.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Myovant Sciences

Specialty Biopharmaceuticalsmyovant.com

Myovant Sciences is a specialty biopharmaceutical company developing relugolix-based therapies — ORGOVYX for advanced prostate cancer and MYFEMBREE for women's health — serving prostate cancer patients and women with endometriosis and uterine fibroids as a Sumitovant Biopharma subsidiary.

What Myovant Sciences does

Myovant Sciences is a specialty biopharmaceutical company developing and commercializing novel small-molecule therapies built on the relugolix platform. Its two marketed products are ORGOVYX (relugolix), indicated for advanced prostate cancer treatment, and MYFEMBREE (relugolix, estradiol, and norethindrone acetate), positioned across women's health indications including endometriosis and uterine fibroids. The company serves defined patient populations — men with advanced or castration-sensitive prostate cancer and women with endometriosis/uterine fibroids — through an enterprise specialty-pharma field-sales motion targeting healthcare providers and payers in the United States (North America accounts for 44.17% regional share of the 2025 endometriosis treatment market where Myovant competes).

Revenue is generated through branded pharmaceutical product sales of ORGOVYX and MYFEMBREE, with pricing negotiated with payers rather than publicly disclosed. The go-to-market relies on traditional specialty-pharma distribution channels reaching physicians and patients. Myovant is actively expanding its endometriosis clinical pipeline to include non-hormonal targeted therapies and long-term disease-management solutions, addressing a market projected to grow from USD 2.01 billion (2025) to USD 5.73–5.74 billion by 2034 at ~12.35–12.37% CAGR. ORGOVYX competes in a castration-sensitive prostate cancer market sized at USD 4.3 billion (2024) with 13.2% CAGR through 2034.

In March 2023, Myovant was acquired by Sumitovant Biopharma Ltd. for $1.7 billion, taking the company private and folding it into the Sumitomo Pharma America corporate ecosystem. Founded in 2016, headquartered in Brisbane, California, and operating with 501–1,000 employees, Myovant raised approximately $540 million across multiple private rounds (2017–2020) prior to acquisition, with Dainippon Sumitomo Pharma, Novaquest Capital Management, and Hercules Capital among its backers. As a wholly owned subsidiary, Myovant now leverages its parent's capital, R&D infrastructure, and commercial reach to accelerate pipeline development and franchise expansion.

Myovant Sciences firmographics

Firmographics
Name
Myovant Sciences
Legal name
Myovant Sciences Ltd.
Website
https://myovant.com
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
501–1,000 employees
Short description
Myovant Sciences is a specialty biopharmaceutical company developing relugolix-based therapies — ORGOVYX for advanced prostate cancer and MYFEMBREE for women's health — serving prostate cancer patients and women with endometriosis and uterine fibroids as a Sumitovant Biopharma subsidiary.
Ownership category
akta.pro rank

Myovant Sciences industry classification

Industry
Product category
Specialty Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKAOAB
Urologic Oncology

Keywords

  • Specialty biopharmaceuticals
  • Prostate cancer therapy
  • Women's health therapeutics
  • Endometriosis treatment
  • Novel drug development

Where Myovant Sciences is headquartered

Location

Headquarters

HQ city
Brisbane
HQ country
United States
HQ region
North America

Markets served

Myovant Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Pharmaceutical product sales: Myovant Sciences generates revenue from commercialization of its proprietary drug products ORGOVYX and MYFEMBREE. As a specialty biopharmaceutical company operating within Sumitovant Biopharma since the March 2023 acquisition, the revenue mix is anchored in product sales of approved therapies, with potential future revenue from expanded indications and pipeline products.

Go-to-market motion1 record

Myovant Sciences product offering

Product offering

Core offering

Myovant Sciences is a specialty biopharmaceutical company that develops and commercializes novel therapies for defined patient populations in prostate cancer and women's health. Its two lead products are ORGOVYX, an oral therapy for advanced prostate cancer, and MYFEMBREE, a therapy for women's health indications including endometriosis and uterine fibroids, supported by an actively expanding clinical pipeline for long-term endometriosis disease management.

Product overview

Myovant Sciences operates as a specialty biopharmaceutical company developing a focused portfolio of novel therapies rather than a platform-plus-modules software product. Its two named therapeutic products, ORGOVYX and MYFEMBREE, are the cornerstone offerings supported by an expanding clinical pipeline in women's health (endometriosis, uterine fibroids) and castration-sensitive prostate cancer. Following its March 2023 acquisition by Sumitovant Biopharma for $1.7 billion, Myovant's portfolio is positioned for accelerated development, and the company is cited as a key pharmaceutical player expanding clinical pipelines for long-term disease management in endometriosis and PCOS.

Differentiator

Problem solved

Functional benefit

Brands

  • ORGOVYX: Novel therapy developed by Myovant Sciences, cited in connection with the Sumitovant acquisition.
  • MYFEMBREE

Products and services

  • ORGOVYX (relugolix)

Quantifiable outcome

  • Acquired by Sumitovant Biopharma for $1.7 billion in March 2023, signaling valuation of Myovant's portfolio of novel therapies.
  • +1 more outcomes

Companies that use Myovant Sciences

Customer profile

Segments3 records

Ideal customer profiles1 record

Myovant Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Myovant Sciences partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Myovant Sciences competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: Global pharmaceutical leader with a major women's health franchise (including Orilissa/Oriahnn for endometriosis) and oncology portfolio. Directly comparable as a key competitor cited in the endometriosis market alongside Myovant.
  • Bayer AG: Diversified life sciences company with a significant women's health and oncology portfolio (e.g., Visanne for endometriosis). Named alongside Myovant as a key endometriosis market player.
  • Pfizer: Global pharmaceutical leader with established women's health and oncology franchises. Cited alongside Myovant as a key pharmaceutical company expanding endometriosis clinical pipelines.
  • AstraZeneca: Global biopharmaceutical company with major oncology and women's health franchises. Comparable to Myovant as a broader incumbent with overlapping therapeutic areas.
  • Eli Lilly: Diversified global pharmaceutical leader with significant oncology and women's health investments. Comparable broad-incumbent competitor operating in Myovant's therapeutic categories.

Direct peers

  • Astellas Pharma: Specialty biopharmaceutical company with deep urology and prostate cancer franchise (Xtandi). Directly comparable to Myovant's ORGOVYX positioning in advanced prostate cancer.
  • Organon & Co. Women's health-focused specialty biopharmaceutical company spun out from Merck. Directly comparable to Myovant's MYFEMBREE franchise in endometriosis and uterine fibroids.
  • TherapeuticsMD: Specialty women's health biopharmaceutical company focused on hormone-related therapeutics, including uterine fibroid and menopause indications. Closely aligned with Myovant's MYFEMBREE women's health portfolio.
  • Ferring Pharmaceuticals: Specialty biopharmaceutical company with established reproductive health and urology franchises. Directly comparable specialty peer to Myovant in women's health and prostate cancer therapeutics.
  • Tolmar Pharmaceuticals: Specialty pharmaceutical company focused on urology and oncology, including prostate cancer treatments. Directly comparable specialty competitor to Myovant in the urologic oncology space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Myovant Sciences social profiles

Digital presence

Myovant Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Myovant Sciences leadership team

Management profile

Number of profiles

Profiles5 records

Myovant Sciences funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Myovant Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Myovant Sciences

What does Myovant Sciences do?

Myovant Sciences is a specialty biopharmaceutical company that develops and commercializes novel therapies for defined patient populations in prostate cancer and women's health. Its two lead products are ORGOVYX, an oral therapy for advanced prostate cancer, and MYFEMBREE, a therapy for women's health indications including endometriosis and uterine fibroids, supported by an actively expanding clinical pipeline for long-term endometriosis disease management.

Is Myovant Sciences a public or private company?

Myovant Sciences is a private company. It is classified as corporate owned and is currently acquired.

When was Myovant Sciences founded?

Myovant Sciences was founded in 2016. It employs 501 to 1,000 people.

Where is Myovant Sciences based?

Myovant Sciences is headquartered in Brisbane, United States, in the North America region.

How does Myovant Sciences make money?

One revenue line is on record: pharmaceutical product sales.

Who are Myovant Sciences's main competitors?

Broad incumbents on record are AbbVie, Bayer AG, Pfizer, AstraZeneca and Eli Lilly. Direct peers are Astellas Pharma, Organon & Co., TherapeuticsMD, Ferring Pharmaceuticals and Tolmar Pharmaceuticals.

Does Myovant Sciences have an API?

No public API is recorded for Myovant Sciences.

What industry is Myovant Sciences in?

Myovant Sciences's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAKAOAB, Urologic Oncology. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comEmerging Growth Trends Driving Rapid Expansion in the Fertility Supplement MarketThe fertility supplement market is projected to reach $2.8 billion by 2030 with a compound annual growth rate of 7.6%, driven by advancements in fertility-specific formulations, increased preventive reproductive health focus, and rising demand for personalized supplements. In March 2023, Sumitovant Biopharma Ltd. acquired Myovant Sciences Ltd. for $1.7 billion to combine expertise and accelerate development of novel therapies including ORGOVYX and MYFEMBREE. The market is further shaped by companies investing in technological innovations such as wearable microfluidic patches for health monitoring.Straits ResearchEndometriosis Treatment Market Size, Share, Growth, Analysis, 2034The global endometriosis treatment market is valued at USD 2.01 billion in 2025 and is projected to reach USD 5.73 billion by 2034, growing at a CAGR of 12.37%, driven by rising disease prevalence and advancements in non-hormonal targeted therapies and AI-driven diagnostic tools. North America held the dominant regional share at 44.17% in 2025, while the Asia Pacific region is anticipated to register the fastest growth with a CAGR of 14.48%. The oral route of administration dominated the market with a 57.89% revenue share, and key pharmaceutical companies including AbbVie, Bayer, Pfizer, and Myovant Sciences are expanding their clinical pipelines for long-term disease management solutions.PR NewswireEndometriosis Treatment Market to Surge to US$ 3.1 Billion by 2034: Innovations in Surgical Procedures and Fertility-Preserving Medications Drive Market Growth | TMRTransparency Market Research projects the global endometriosis treatment market to grow from US$1.4 billion in 2023 to US$3.1 billion by 2034, representing a compound annual growth rate of 7.5%, driven by innovations in surgical procedures and fertility-preserving medications. Key regulatory milestones include the FDA's August 2022 approval of MYFEMBREE (developed by Myovant Sciences and Pfizer) for managing endometriosis-associated pain, and positive Phase 3 trial results for linzagolix announced by ObsEva SA in January 2022. Research efforts continue to focus on developing treatments that effectively manage symptoms without compromising fertility, with ongoing clinical trials and support from agencies such as the DBT/Wellcome India Alliance.PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOVPomerantz LLP announced it is investigating securities fraud claims on behalf of investors in Myovant Sciences regarding a merger where Sumitovant Biopharma agreed to acquire all outstanding Myovant shares not already owned for $27.00 per share. The complaint alleges that the proxy statement misleadingly stated that Skadden had no conflicts of interest when the law firm was simultaneously representing Sumitomo Pharma affiliates, violating securities laws and causing shareholders to approve the merger at less than full value.PR NewswireTLV, den svenske styrelse for læge- og tandlægemiddelydelser har d. 19. oktober besluttet, at ORGOVYX® (relugolix), tabletter til behandling at fremskreden, hormonfølsom prostatakræft i Sverige fra d.The Swedish Dental and Pharmaceutical Benefits Agency (TLV) decided on October 19 to provide subsidy coverage for Orgovyx (relugolix), the first oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in Sweden. Accord Healthcare, selected by Myovant Sciences as commercial partner for European marketing, announced that the treatment is now accessible to patients, offering faster testosterone reduction and fewer side effects compared to injectable alternatives. Prostate cancer is the most common cancer among men in Sweden, with approximately 10,000 new cases diagnosed annually.PR NewswireTand och läkemedelsförmånsnämnden, TLV, har den 19 oktober beslutat att ORGOVYX® (relugolix), tabletter för behandling av avancerad hormonkänslig prostatacancer i Sverige ska inkluderas i läkemedelsföSweden's TLV (Tandvårds- och läkemedelsförmånsverket) decided on October 19 to include Orgovyx (relugolix), an oral GnRH-antagonist tablet for advanced hormone-sensitive prostate cancer, in the Swedish pharmaceutical benefits scheme. Orgovyx, developed by Myovant Sciences and commercialized in Europe by Accord Healthcare following EMA approval in April 2022, is the first oral castration therapy available in Sweden, offering a faster and more convenient alternative to injectable treatments. The TLV concluded that Orgovyx's clinical efficacy is significantly better than leuprorelin and its cost is reasonable for treating a high-severity condition affecting approximately 10,000 new patients annually in Sweden.PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOVPomerantz LLP has launched an investigation into Myovant Sciences and its officers regarding potential securities fraud in connection with the $27.00-per-share acquisition of Myovant by Sumitovant Biopharma, a subsidiary of Sumitomo Pharma. The complaint alleges that the proxy statement used to solicit shareholder approval of the merger contained material misrepresentations, specifically failing to disclose that Skadden, the Special Committee's legal advisor, was simultaneously representing Sumitomo Pharma affiliates—creating conflicts of interest. Shareholders allegedly voted to approve the merger at below fair value as a result of these alleged misrepresentations, which violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9.PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOVPomerantz LLP announced it is investigating claims on behalf of investors of Myovant Sciences, Ltd. regarding potential securities fraud and unlawful business practices by the company and its officers and directors. The investigation centers on a merger where Sumitovant Biopharma agreed to acquire all outstanding Myovant shares that Sumitovant did not already own for $27.00 per share in cash. A complaint alleges that the definitive proxy statement contained material misrepresentations and omissions, specifically that legal advisor Skadden, Arps, Slate, Meagher & Flom LLP had undisclosed conflicts of interest due to its simultaneous representation of Sumitomo Pharma affiliates when retained by Myovant's special committee, which misled shareholders into approving the merger at a price below the company's full and fair value.PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOVPomerantz LLP announced an investigation into claims on behalf of investors of Myovant Sciences, Ltd. concerning alleged securities fraud related to Sumitovant Biopharma's acquisition of Myovant. The investigation centers on a January 2023 proxy statement that allegedly contained material misrepresentations about conflicts of interest involving legal advisor Skadden, Arps, Slate, Meagher & Flom LLP, which was simultaneously representing Sumitomo Pharma affiliates while advising Myovant's special committee on the merger. The complaint alleges that these undisclosed conflicts misled shareholders into approving the $27.00-per-share merger at less than the company's full and fair value.